Skip to main content
SpringerLink
Log in

Circulating microRNAs as novel biomarkers in the diagnosis of prostate cancer: a systematic review and meta-analysis

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Background

The diagnostic value of circulating microRNAs (miRNAs) detection in prostate cancer (PC) patients is currently under debate. Thus, we performed this meta-analysis of published literature to systematically evaluate the diagnostic potential of circulating miRNAs in PC.

Methods

Eligible studies were searched in PubMed, Embase and Chinese National Knowledge Infrastructure databases. Sensitivity and specificity were pooled using a random-effects model and were used to plot the summary receiver operator characteristic (SROC) curve. All analyses were performed using the Stata 13.0 software and Meta-Disc 1.4 for windows.

Results

A total of ten articles were included for the meta-analysis according to the inclusion criteria. The pooled results based on all included studies showed circulating miRNAs have a relatively good diagnostic performance, with a sensitivity of 0.74, a specificity of 0.71 and an area under SROC curve (AUC) of 0.77 in indiscriminating PC from controls. Furthermore, meta-regression and subgroup analyses indicate that multiple circulating miRNAs detection displayed a better diagnostic performance than single one, with an AUC rising from 0.75 to 0.81. Additional interesting finding was that Caucasian-based circulating miRNAs assays could reach a higher accuracy compared with non-Caucasian-based one for PC with the p value of 0.0378.

Conclusion

Our results confirmed the potential use of circulating miRNAs in the early diagnosis of PC, especially the combination of multiple circulating miRNAs. However, large-scale prospective studies are still needed to further validate our findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics. CA Cancer J Clin 64(1):9–29

    Article  PubMed  Google Scholar 

  2. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349(3):215–224

    Article  CAS  PubMed  Google Scholar 

  3. Dall’Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L et al (2008) Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112(8):1650–1659

    Article  PubMed  Google Scholar 

  4. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R (2006) Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20(5):515–524

    Article  CAS  PubMed  Google Scholar 

  5. Inui M, Martello G, Piccolo S (2010) MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 11(4):252–263

    Article  CAS  PubMed  Google Scholar 

  6. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997–1006

    Article  CAS  PubMed  Google Scholar 

  7. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S et al (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99(24):15524–15529

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65(16):7065–7070

    Article  CAS  PubMed  Google Scholar 

  9. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS et al (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58(10):1375–1381

    Article  CAS  PubMed  Google Scholar 

  10. Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, Scheffler M, Huwer H, Lenhof HP, Meese E (2009) miRNAs in lung cancer—studying complex fingerprints in patient’s blood cells by microarray experiments. BMC Cancer 9:353

    Article  PubMed  PubMed Central  Google Scholar 

  11. Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, Shen HB, Zhang CY et al (2010) Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 70(23):9798–9807

    Article  CAS  PubMed  Google Scholar 

  12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30):10513–10518

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J (2011) Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77(5):1265–1269

    Article  PubMed  Google Scholar 

  14. Yaman AF, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, Gezer U (2011) Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 32(3):583–588

    Article  Google Scholar 

  15. Zhang HL, Qin XJ, Cao DL, Zhu Y, Yao XD, Zhang SL, Dai B, Ye DW (2013) An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian J Androl 15(2):231–235

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536

    Article  PubMed  Google Scholar 

  17. Walter SD (2002) Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 21(9):1237–1256

    Article  CAS  PubMed  Google Scholar 

  18. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560

    Article  PubMed  PubMed Central  Google Scholar 

  19. Dinnes J, Deeks J, Kirby J, Roderick P (2005) A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess 9(12):1–113

    Article  CAS  Google Scholar 

  20. Jackson D, White IR, Thompson SG (2010) Extending DerSimonian and Laird’s methodology to perform multivariate random effects meta-analyses. Stat Med 29(12):1282–1297

    Article  PubMed  Google Scholar 

  21. Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58(9):882–893

    Article  PubMed  Google Scholar 

  22. Kachakova D, Mitkova A, Popov E, Popov I, Vlahova A, Dikov T, Christova S, Mitev V et al (2015) Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer. DNA Cell Biol 34(3):189–200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Srivastava A, Goldberger H, Dimtchev A, Marian C, Soldin O, Li X, Collins SP, Suy S et al (2014) Circulatory miR-628-5p is downregulated in prostate cancer patients. Tumour Biol 35(5):4867–4873

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kotb S, Mosharafa A, Essawi M, Hassan H, Meshref A, Morsy A (2014) Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancer. Tumour Biol 35(12):12613–12617

    Article  CAS  PubMed  Google Scholar 

  25. Egidi MG, Cochetti G, Serva MR, Guelfi G, Zampini D, Mechelli L, Mearini E (2013) Circulating microRNAs and kallikreins before and after radical prostatectomy: are they really prostate cancer markers? BioMed Res Int 2013:241780

    Article  PubMed  PubMed Central  Google Scholar 

  26. Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM, Yang J (2012) A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 72(13):1443–1452

    Article  CAS  PubMed  Google Scholar 

  27. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T et al (2012) Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106(4):768–774

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Liao YF, Dai JH, Mao QF (2014) Circulating miRNA-141 as a non-invasive biomarker for prostate cancer detection and prognosis. Chin J Pathol 30(10):1887–1890

    CAS  Google Scholar 

  29. Papagiannakopoulos T, Shapiro A, Kosik KS (2008) MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 68(19):8164–8172

    Article  CAS  PubMed  Google Scholar 

  30. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, Li Y (2008) MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27(31):4373–4379

    Article  CAS  PubMed  Google Scholar 

  31. Yang Q, Zheng Y, Zhu D (2014) Diagnostic performance of microRNAs expression in prostate cancer. Tumour Biol 35(10):10529–10538

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by National Natural Science Foundation of China (No. 81371897) and Hubei Province health and family planning scientific research project (WJ2015MB032). This work was also funded by “351 talent project (Luojia Young Scholars)” of Wuhan University.

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuchang District, Wuhan, 430071, People’s Republic of China

    Changqing Yin & Fubing Wang

  2. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuchang District, Wuhan, 430071, People’s Republic of China

    Cheng Fang & Hong Weng

  3. Department of Immunology, School of Basic Medical Sciences, Wuhan University, No. 185 Donghu Road, Wuchang District, Wuhan, 430071, People’s Republic of China

    Chunhui Yuan

Authors
  1. Changqing Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cheng Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong Weng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chunhui Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fubing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fubing Wang.

Ethics declarations

Conflict of interest

No potential conflicts of interests were disclosed.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yin, C., Fang, C., Weng, H. et al. Circulating microRNAs as novel biomarkers in the diagnosis of prostate cancer: a systematic review and meta-analysis. Int Urol Nephrol 48, 1087–1095 (2016). https://doi.org/10.1007/s11255-016-1281-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-016-1281-4

Keywords

Search

Navigation